January 2007 Oncology News International

A post hoc ReFocus analysis found prior immune checkpoint inhibitor exposure raised the risk of mucocutaneous AEs with lirafugratinib.

Data from the real-world CEMI-LUNG evaluating cemiplimab in advanced NSCLC were consistent with reports from the EMPOWER-Lung1 study.

A cisplatin-free pembrolizumab regimen yielded 65.1% laryngectomy-free survival rate at 2 years in SMART-KEY, missing significance vs historical controls.

Data from the phase 3 CERVINO trial support the application for etentamig as a treatment for adults with relapsed or refractory multiple myeloma.

Risvutatug rezetecan cut the risk of progression or death by 67% vs gemcitabine/docetaxel in heavily pretreated R/R osteosarcoma in ARTEMIS-011.

Two-year MANEUVER data show durable, deepening responses and sustained gains in pain, stiffness, and function with pimicotinib in TGCT.

The MagnetisMM-32 trial may support elranatamab as an important option for those whose disease has progressed following anti-CD38 therapy and lenalidomide.

At Big Ten CRC, Patricia A. Robinson, MD, discussed institutional and cooperative group strategies that have improved representation in oncology clinical trials.